• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Deals

Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand
Biotech

BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect

BioMarin has followed through on its shift to external innovation, inking a deal to add a phase 3 enzyme replacement therapy to its pipeline.
Nick Paul Taylor May 16, 2025 8:46am
hearing deaf pediatrics audiologist doctor children

Lilly strengthens RNA pipeline with $1.3B hearing loss pact

May 16, 2025 7:34am
handshake deal shake hand arrows ok yes

AbbVie tosses ADARx $335M for siRNA options deal

May 14, 2025 9:00am
merge MA railway train tracks path together

Activist investor fails to derail Alumis' Acelyrin merger

May 14, 2025 7:45am
finance numbers tape money

Novo inks $2.2B deal for Septerna's preclinical obesity programs

May 14, 2025 7:00am
GlaxoSmithKline

GSK pays $1.2B upfront for Boston's lead liver disease drug

May 14, 2025 2:53am
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings